Adams, RichardBrown, EwanBrown, LouiseButler, RachelFalk, StephenFisher, DavidKaplan, RichardQuirke, PhilRichman, SusanSamuel, LeslieSeligman, JennySeymour, MattShui, Kai KeenWasan, HarpreetWilson, RichardMaughan, Tim2018-04-022018-04-022018-03Adams, R, Brown, E, Brown, L, Butler, R, Falk, S, Fisher, D, Kaplan, R, Quirke, P, Richman, S, Samuel, L, Seligman, J, Seymour, M, Shui, K K, Wasan, H, Wilson, R & Maughan, T 2018, 'Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D) : a phase 2–3 randomised trial', The Lancet Gastroenterology & Hepatology, vol. 3, no. 3, pp. 162–171. https://doi.org/10.1016/S2468-1253(17)30394-1ORCID: /0000-0002-8402-8670/work/50559777http://hdl.handle.net/2164/10279This study was funded by the UK Medical Research Council (MRC) and National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation programme; Cancer Research UK; NIHR Clinical Trials Research Network; Health and Care Research Wales (and equivalent in devolved nations); and AstraZeneca Drug Supply and Distribution. PQ, MS, and SR received programme grant support from Yorkshire Cancer Research. PQ is an NIHR Senior Investigator at the Department of Pathology Cardiff and Vale University Health Board, All Wales Genetics Laboratories, Wales Cancer Bank. The MRC Clinical Trials Unit at University College London receives funding from the MRC (programme grant MC_UU_12023/20).9427495engSDG 3 - Good Health and Well-beingcolorectal cancerbiomarkerstherapeutic efficacyEGFR inhibitorsR MedicineCancer Research UKMedical Research Council (MRC)National Institute for Health Research (NIHR)RJournal article10.1016/S2468-1253(17)30394-133